ImCheck Therapeutics
Elisabeth Wieduwild has a diverse work experience spanning several companies and roles. Elisabeth started their career in 2010 as an Undergraduate Student Researcher at the Leibniz Institute of Plant Biochemistry, where they focused on characterizing proteins involved in plant protection against worms. In 2012, they became an Undergraduate Student Researcher at Scil Proteins GmbH, gaining experience in protein expression, purification, and characterization. Elisabeth then joined CIML in 2014, first as a Technicien, and later as a PHD Graduate Student, studying the regulation of immune functions by the nervous system. Elisabeth also spent a year abroad with an ERASMUS+ fellowship in the lab of Eric Vivier at CIML. In 2020, Elisabeth started working as a Postdoctoral Scientist at CENTURI - Turing Centre for Living Systems, conducting research with Dr. Mauro GAYA and Dr. Marie-Pierre VALIGNAT. Currently, in 2022, Elisabeth is a Scientist at Imcheck Therapeutics.
Elisabeth Wieduwild began their education journey at The Martin Luther University of Halle-Wittenberg in 2007, where they pursued a Bachelor's degree in Biochimie. Elisabeth successfully completed their undergraduate studies in 2011. Following this, they proceeded to pursue a Master's degree in Biochimie at the same university, which they successfully obtained in 2014.
Continuing their academic pursuits, Elisabeth enrolled at Aix-Marseille University in 2016 to pursue a Doctor of Philosophy (PhD) degree in Immunologie. Their doctoral studies spanned from 2016 to 2019, where they likely conducted extensive research and gained expertise in their chosen field of study.
ImCheck Therapeutics
1 followers
ImCheck Therapeutics is a developer of immuno-modulatory antibodies designed for the treatment of cancer and other immune-related diseases. The company's services are engaged in the discovery and development of immunomodulators for treating breast cancer, gastric, ovarian cancer cells and other solid solid tumours.